Frequência dos polimorfismos nos genes NLRP1, NLRP3, P2X7, IL1B e IL18 em pacientes com Leucemia Linfoblástica Aguda e sua influência no prognóstico clínico
Carregando...
Arquivos
Data
Autores
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade do Estado do Amazonas
Resumo
The dysregulation of the activation of the inflammasome complex by the presence
of Single Nucleotide Polymorphisms (SNPs) is pointed out as one of the factors
that promote neoplastic activity in the hematopoietic stem cell. Although the SNPs
involving these complexes are associated with the manifestation of infectious and
non-infectious diseases, the relationship with susceptibility or prognosis in
leukemia patients in the Brazilian Amazon is still unknown. Thus, the aim of this
study was to describe the frequency of polymorphisms in the NLRP1 (rs12150220
and rs35865013), NLRP3 (rs10750558 and rs10802502) genes, P2X7
(rs2230911 and rs3751143), IL1β (rs16944) and IL18 (rs187238) and its
influence on clinical prognosis. A case-control study was carried out with 158
patients with ALL and 192 control individuals from a region of the Brazilian
Amazon, the State of Amazonas. The genetic polymorphisms in the IL1β and
IL18 genes were genotyped from the restriction fragment length polymerase-
polymorphism chain reaction (PCR-RFLP). While the polymorphisms in the
NLRP1, NLRP3 and P2X7 genes were genotyped using Real Time Quantitative
PCR (qPCR). The IL1β C/T rs19644 genotype was associated with the risk of
ALL development (C/C vs. C/T + T/T OR: 2.48 [95% CI: 1.26 - 4.88, p = 0.006];
CC vs C/T OR: 2.74 [95% CI: 1.37-5.51, p = 0.003]). The genotypes P2X7 A/C
rs3751143 (OR: 2.30 [95% CI: 1.05-5.03, p= 0.036]) and NLRP3 G/G rs10754558
(OR: 7.44 [95% CI: 1.44 - 38.26, p = 0.016]) were associated with the risk of
infectious comorbidities whereas, NLRP1 A/T rs12150220 (OR: 0.37 [95% CI:
0.16 - 0.87, p = 0.023]) was associated with protection against comorbidities. In
addition, the association of the genotype NLRP1 A/G rs35865013 (OR: 2.72 [95%
CI: 1.07 - 6.90, p = 0.034]) with the risk of relapse after treatment in ALL patients
has been described. The variant IL1β rs16944 seems to predispose individuals
from the Brazilian Amazon region to ALL. In addition, inflammasome SNPs are
xi
associated with the presence of infectious comorbidities and relapse episodes
throughout treatment in individuals with acute lymphoblastic leukemia